Latest News on EDIT

Financial News Based On Company


Advertisement
Advertisement

Sickle Cell Drug: Marrow Raises $173 Million Without Releasing Anemia or Selectivity Data

https://www.techtimes.com/articles/330910/20261117/sickle-cell-drug-marrow-raises-173-million-without-releasing-anemia-selectivity-data.htm
Marrow Therapeutics launched with $173 million in Series A and B financing to develop MAR-101, a sickle cell and beta thalassemia drug that targets the fetal hemoglobin repressor BCL11A. The drug, which has not yet been tested in humans, aims to be an alternative to gene therapy but lacks public data on its ability to spare red cells' iron supply and selectively silence BCL11A. Investors include OrbiMed, Scion Life Sciences, and venBio, funding manufacturing efforts for global access.

Have Editas Medicine Insiders Been Selling Stock?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-edit/editas-medicine/news/have-editas-medicine-insiders-been-selling-stock
Editas Medicine's President, Gilmore O’Neill, recently sold US$51k worth of stock at US$2.42 per share, reducing his holding by 9.1%. Despite this, the sale occurred above the current share price of US$2.17. Over the last year, there have been no insider stock purchases, and insider ownership remains low, which combined with recent sales, suggests a lack of insider confidence in the stock.

Editas Medicine reports potential of EDIT-401 therapy for hyperlipidemia in fresh study

https://tradersunion.com/news/companies/show/4222486-editas-edit401-hyperlipidemia-data/
Editas Medicine announced new preclinical data for its investigational therapy EDIT-401, demonstrating its potential for durable treatment of hyperlipidemia. These findings were presented at AHA2026 and suggest that EDIT-401 could be a transformative therapeutic option. The company continues to advance its research pipeline, with previous presentations at the ESGCT 33rd Annual Congress and investor conferences.

Editas Medicine, Inc. (NASDAQ:EDIT) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-edit/editas-medicine/news/editas-medicine-inc-nasdaqedit-just-reported-third-quarter-e
Editas Medicine (NASDAQ:EDIT) reported third-quarter results that surpassed expectations, with revenues of US$10m and a statutory loss per share of US$0.15, beating analyst forecasts. Despite this, analysts predict a significant revenue decline of 62% in 2027 to US$19.0m and increased losses of US$0.69 per share. The consensus price target remained at US$6.10, indicating that the adjustments to revenue and earnings are not expected to have a long-term impact on the business.

Editas Medicine Plans Human Trial After Gene Therapy Slashed LDL 90% in Primate Study

https://www.tradingview.com/news/marketbeat:ecb603573094b:0-editas-medicine-plans-human-trial-after-gene-therapy-slashed-ldl-90-in-primate-study/
Editas Medicine is preparing to initiate a Phase I/II human trial for its gene-editing candidate, EDIT-401, targeting high LDL cholesterol. Preclinical studies in nonhuman primates demonstrated a 90% reduction in LDL cholesterol that was durable for 10 months. The company aims for over 60% LDL reduction in humans and expects to report initial safety data in Q1 and top-line efficacy data in H2 2027.
Advertisement

Editas Medicine Plans Human Trial After Gene Therapy Slashed LDL 90% in Primate Study

https://finance.yahoo.com/healthcare/articles/editas-medicine-plans-human-trial-221445546.html
Editas Medicine is preparing to initiate a Phase I/II human trial for its gene-editing therapy, EDIT-401, targeting heterozygous familial hypercholesterolemia. The therapy previously achieved a 90% reduction in LDL cholesterol in nonhuman primates, an effect that lasted for 10 months. The company aims for over 60% LDL reduction in humans while prioritizing safety, with initial safety data expected in Q1 2027 and efficacy data in H2 2027.

Editas Medicine Announces Third Quarter 2026 Results and Business Updates

https://www.quantisnow.com/insight/editas-medicine-announces-third-quarter-2026-results-and-business-updates-6780039
Editas Medicine reported its third-quarter 2026 results, announcing a narrowed net loss of $0.15 per share and a cash runway extending into the second half of 2028. The company also received Australian regulatory approval to begin its Phase 1/2 Strive study for EDIT-401 in hyperlipidemia, with initial safety data expected in Q1 2027. Despite increased R&D and administrative expenses, the positive preclinical data for EDIT-401 and a milestone payment from Bristol Myers Squibb are seen as positive developments for shareholders.

EDITAS MEDICINE ($EDIT) Releases Q3 2026 Earnings

https://www.quiverquant.com/news/EDITAS+MEDICINE+%28%24EDIT%29+Releases+Q3+2026+Earnings
EDITAS MEDICINE ($EDIT) reported its Q3 2026 earnings, surpassing analyst estimates for both earnings per share and revenue. The company posted -$0.15 per share, beating the -$0.19 estimate, and recorded revenue of $10,370,000, significantly exceeding the $4,549,118 estimate. The article also details recent insider trading activity, primarily sales, and significant increases in institutional holdings from various hedge funds.

EDIT: EDIT-401 nears first dosing as durable preclinical results and cash runway support execution into 2028

https://www.tradingview.com/news/urn:summary_document_report:quartr.com:3969861:0-edit-edit-401-nears-first-dosing-as-durable-preclinical-results-and-cash-runway-support-execution-into-2028/
Editas Medicine (EDIT) is nearing the first dosing for EDIT-401, with clearance of Australian ethics and trial-notification steps. The first dosing is targeted for 2026, and initial data is expected in Q1 2027. The company's Q3 revenue rose year-over-year, its net loss narrowed, and its cash resources are projected to extend into the second half of 2028.

An experimental gene-editing treatment kept LDL cholesterol down at least 90% for 10 months in primates.

https://www.stocktitan.net/news/EDIT/editas-medicine-announces-third-quarter-2026-results-and-business-jyey00l1zuur.html
Editas Medicine announced its third-quarter 2026 financial results, reporting a narrower net loss and increased revenue, primarily due to partner milestones. The company highlighted new preclinical data for its gene-editing treatment EDIT-401, showing sustained LDL cholesterol reductions of at least 90% for 10 months in non-human primates, supporting its potential as a one-time treatment for hyperlipidemia. Editas also confirmed the initiation of the Phase 1/2 Strive study for EDIT-401 in Australia and a milestone payment from Bristol Myers Squibb for a CAR-T therapy collaboration.
Advertisement

Form 4 Editas Medicine: Gilmore Neil O’Neill (Director, CEO) For: 5 November

https://ca.investing.com/news/stock-market-news/form-4-editas-medicine-gilmore-neil-oneill-director-ceo-for-5-november-93CH-4940301
This article reports on a Form 4 filing for Editas Medicine, specifically noting a transaction by Gilmore Neil O’Neill, who serves as a Director and CEO of the company. The filing is dated November 5, but the article announcing it was published on November 6, 2026. The brief piece indicates that the information is related to insider trading activity.

Linda Burkly Acquires 16,533 Editas Medicine Shares Following R&D Milestone Vesting

https://kalkinemedia.com/us/news/announcements/linda-burkly-acquires-16533-editas-medicine-shares-following-rd-milestone-vesting
Linda Burkly, EVP and Chief Scientific Officer at Editas Medicine, Inc., acquired 16,533 common stock shares on November 5, 2026. This acquisition resulted from the vesting of a performance-based restricted stock unit, triggered by the achievement of a specific research and development milestone. Following this transaction, Burkly's direct ownership in Editas Medicine now totals 78,193 shares.

Editas Medicine CEO Gilmore O'Neill Vests 43,567 Shares Following R&D Milestone Achievement

https://kalkinemedia.com/us/news/announcements/editas-medicine-ceo-gilmore-oneill-vests-43567-shares-following-rd-milestone-achievement
Gilmore O'Neill, CEO and Director of Editas Medicine, Inc., vested 43,567 shares of common stock on November 5, 2026. This vesting was a result of achieving a specific research and development milestone tied to a performance-based restricted stock unit award granted in March 2024. Following this transaction, O'Neill directly owns 286,756 shares of Editas Medicine common stock.

Editas Medicine (NASDAQ:EDIT) Stock Breaks Below Two Hundred Day Moving Average - Time to Sell?

https://www.marketbeat.com/instant-alerts/price-editas-medicine-nasdaq-edit-stock-breaks-below-two-hundred-day-moving-average-time-to-sell-2026-11-06/
Editas Medicine (NASDAQ:EDIT) shares have fallen below their 200-day moving average, trading at $2.55, below the $2.68 average. Despite the price drop, analyst sentiment remains a "Moderate Buy" with an average price target of $5.83. The company also reported better-than-expected quarterly earnings and revenue.

Recombinant DNA Technology Market: Industry Developments

https://www.openpr.com/news/4683792/recombinant-dna-technology-market-industry-developments
The recombinant DNA technology market is experiencing significant growth, projected to reach $1,414.92 billion by 2030, driven by advancements in gene editing and increasing demand across healthcare, agriculture, and environmental sectors. Key trends include the adoption of CRISPR technology, development of recombinant vaccines, and expansion of cell and gene therapy pipelines. Major players like Amgen, Novartis, and Pfizer are leading innovation, with notable developments such as SK bioscience's acquisition of IDT Biologika and FDA approval for Vertex Pharmaceuticals' CRISPR-enabled therapy, Casgevy.
Advertisement

Jones Trading initiates Editas Medicine stock coverage with buy rating By Investing.com

https://ca.investing.com/news/stock-market-news/jones-trading-initiates-editas-medicine-stock-coverage-with-buy-rating-93CH-4934023
Jones Trading has initiated coverage on Editas Medicine (NASDAQ:EDIT) with a Buy rating and an $8.00 price target, indicating significant upside potential from its current trading price of $2.72. The valuation is primarily based on their lead asset, EDIT-401, a gene editor for LDL cholesterol, with initial data expected in late 2027. Despite concerns about commercial viability and cash burn, the company's strong balance sheet and comparable market validations like Eli Lilly's acquisition of Verve underscore its potential.

Editas Medicine stock trades at EUR 2.46 before Q3 results

https://www.ad-hoc-news.de/boerse/news/nebenwerte/editas-medicine-stock-trades-at-eur-2-46-before-q3-results/70460416
Editas Medicine is set to report its third-quarter results on November 9, 2026, with investors closely watching the progress of its lead gene-editing program, EDIT-401, which is moving towards clinical dosing. The stock recently traded at 2.46 euros on Lang & Schwarz. Key upcoming milestones include patient dosing in the Strive trial in Australia and New Zealand, new preclinical durability data, and initial safety results targeted for Q1 2027.

The In-vivo Prime Editing Platform Market Is Projected to Grow to $4.52 Billion by 2030

https://www.openpr.com/news/4681962/the-in-vivo-prime-editing-platform-market-is-projected-to-grow
The in-vivo prime editing platform market is experiencing rapid growth, driven by advancements in genetic editing technologies and increased funding for biotechnology. Projected to reach $4.52 billion by 2030 from $1.26 billion in 2025, this expansion is fueled by clinical adoption of prime editing, in-vivo gene therapies, and strategic collaborations. Key players like AstraZeneca, Danaher, and Moderna are innovating in delivery systems and gene therapy applications, with a notable acquisition of Verve Therapeutics by Eli Lilly to advance cardiovascular genetic treatments.

In Vivo Gene Editing Market Advances as Intellia Reports 87% Reduction in Disease Attacks in Landmark Phase 3 Trial

https://www.openpr.com/news/4680381/in-vivo-gene-editing-market-advances-as-intellia-reports-87
The global In Vivo Gene Editing Market is experiencing significant growth, projected to reach USD 37.75 billion by 2035, driven by clinical successes like Intellia Therapeutics' Phase 3 HAELO trial. This trial showed an 87% reduction in hereditary angioedema attacks, leading to an FDA Priority Review for its CRISPR-based therapy. The market's expansion is further supported by advancements in non-viral delivery technologies and increasing investments in genetic medicines, with North America leading and Asia-Pacific being the fastest-growing region.

The Base-Editing Tools Market Is Projected to Grow at a 21.4% CAGR Through 2030

https://www.openpr.com/news/4679379/the-base-editing-tools-market-is-projected-to-grow-at-a-21-4-cagr
The base-editing tools market is forecast to grow at a 21.4% CAGR, reaching $4.82 billion by 2030, driven by advancements in precision medicine and gene therapy. Key factors include rising demand for precise medical treatments, growth in biotech startups, and regulatory clearances. Influential companies like Thermo Fisher Scientific and Merck KGaA are leading innovation, with significant acquisitions like Eli Lilly's purchase of Verve Therapeutics enhancing gene-editing capabilities.
Advertisement

Editas Medicine (EDIT) Projected to Announce Earnings on Monday

https://www.marketbeat.com/instant-alerts/upcoming-editas-medicine-edit-projected-to-announce-earnings-on-monday-2026-11-02/
Editas Medicine (EDIT) is expected to report its Q3 2026 earnings before market open on Monday, November 9th, with analysts forecasting a loss of $0.21 per share and revenue of $4.54 million. The company's earnings call is scheduled for November 10th at 4:00 p.m. ET. Editas Medicine previously surpassed estimates in Q2, reporting a smaller loss and higher revenue than expected, and currently holds a "Moderate Buy" consensus rating from Wall Street analysts.

Editas Medicine, Inc. (EDIT) Seasonal returns chart

https://uk.finance.yahoo.com/quote/EDIT/seasonality/
This article presents a seasonal returns chart for Editas Medicine, Inc. (EDIT), displaying the average monthly price return from 2016 to 2026. The stock's current real-time price on NasdaqGS is also provided, along with pre-market data.

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits

https://finance.yahoo.com/healthcare/articles/prme-beam-edit-ntla-crsp-193415060.html
Shares of several gene-editing companies, including Prime Medicine (PRME), Beam Therapeutics (BEAM), Intellia Therapeutics (NTLA), Editas Medicine (EDIT), and CRISPR Therapeutics (CRSP), rallied after the FDA issued draft guidance to accelerate personalized treatments for rare genetic diseases. This new guidance allows companies to file one application for multiple versions of a gene-editing treatment if they make the same kind of genetic correction, enabling faster expansion with lab tests instead of full trials. Prime Medicine saw the largest gains, building on recent company-specific updates, including dosing the first patient in a Phase 1/2 trial for Wilson disease using prime editing therapy.

BlackRock reports a passive stake above 5% in Editas Medicine (EDIT).

https://www.stocktitan.net/sec-filings/EDIT/schedule-13g-editas-medicine-inc-passive-investment-disclosure-5-e70c3311f93a.html
BlackRock, Inc. has filed a Schedule 13G, disclosing a beneficial ownership of 11,937,882 common shares, or 7.8% of the class, in Editas Medicine, Inc. (EDIT) as of September 30, 2026. The filing indicates BlackRock holds sole voting power over 11,732,765 shares and sole dispositive power over 11,937,882 shares. This passive investment reflects holdings by certain BlackRock business units and affiliates, with no single person's interest exceeding 5%.

Editas Medicine, Inc. Estimates – NASDAQ:EDIT

https://www.tradingview.com/symbols/NASDAQ-EDIT/financials-estimates/
This article provides an overview of Editas Medicine, Inc. (NASDAQ: EDIT) financial estimates available on TradingView. It highlights where users can explore reported financial data, analyst estimates across various statements, and visualize trends over time. The page includes sections for income statement, balance sheet, and cash flow, emphasizing that the information is not investment advice.
Advertisement

Total current liabilities of Editas Medicine, Inc. – LSE:0IFK

https://www.tradingview.com/symbols/LSE-0IFK/financials-balance-sheet/total-current-liabilities/
The article provides a brief mention of the total current liabilities for Editas Medicine, Inc., traded on the London Stock Exchange under the symbol 0IFK. It indicates that the market was closed with no trades at the time of the information. The content is primarily boilerplate information from TradingView, focusing on navigation and copyright details rather than specific financial figures.

Editas Medicine, Inc. Estimates – BX:8EM

https://www.tradingview.com/symbols/BX-8EM/financials-estimates/
This article provides an overview of Editas Medicine, Inc. (BX:8EM) on TradingView, focusing on its financial actuals and analyst estimates. Users can explore reported financial data, compare results with average, high, and low estimates, and visualize trends over time across income statements, balance sheets, and cash flow statements. The platform emphasizes that this information is not investment advice and encourages users to conduct their own research.

News: CMN Weekly (23 October 2026) - Your Weekly CRISPR Medicine News

https://crisprmedicinenews.com/news/cmn-weekly-23-october-2026-your-weekly-crispr-medicine-news/
This edition of CMN Weekly highlights significant advancements in CRISPR medicine, including Papillon Therapeutics' PPL-001 therapy for Friedreich’s ataxia heading to trials and Prime Medicine's PM577a entering Phase 1/2 for Wilson disease. Other notable updates cover progress in treatments for glycogen storage disease, alpha-1 antitrypsin deficiency, facioscapulohumeral muscular dystrophy, and primary hyperoxaluria type 1. The report also details new research in gene editing mechanisms, delivery methods, functional genomics, and industry collaborations.

Editas Medicine, Inc. Estimates – LSE:0IFK

https://www.tradingview.com/symbols/LSE-0IFK/financials-estimates/
This article provides an overview of Editas Medicine, Inc. (LSE:0IFK) financial estimates available on TradingView. It directs users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform allows comparison of actual results with average, high, and low estimates, and visualization of trends over time.

Wells Fargo raises target for Editas Medicine stock from USD 4.00 to USD 6.00

https://www.ad-hoc-news.de/boerse/news/nebenwerte/wells-fargo-raises-target-for-editas-medicine-stock-from-usd-4-00-to-usd-6-00/70377351
Wells Fargo has increased its price target for Editas Medicine (EDIT) stock from USD 4.00 to USD 6.00 and upgraded its rating from equal weight to overweight. This adjustment follows Editas Medicine's stronger-than-expected second-quarter 2026 revenue of USD 11.89 million, significantly surpassing the USD 2.85 million consensus estimate. The company's valuation remains heavily dependent on clinical development and its ability to advance gene-editing treatments.
Advertisement

Editas Medicine stock last stood at EUR 2.15 on October 16, 2026, 45.00 percent below high

https://www.ad-hoc-news.de/boerse/news/nebenwerte/editas-medicine-stock-last-stood-at-eur-2-15-on-october-16-2026-45-00-percent-below-high/70350128
Editas Medicine (EDIT) stock was at EUR 2.15 on October 16, 2026, 45.00 percent below its 52-week high of USD 4.28. The company's market capitalization was USD 360.9 million, and it had gained 14.60 percent year-to-date. The next earnings report is scheduled for November 9, 2026, and the company recently received approval for a Phase 1/2 trial of EDIT-401 in Australia.

Editas Medicine, Inc. (EDIT) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/EDIT/
This article provides a comprehensive overview of Editas Medicine, Inc. (EDIT) stock, including its real-time price, historical data, financial performance, and analyst ratings. Editas Medicine, a clinical-stage genome editing company, focuses on developing genomic medicines using CRISPR technology, with its lead program being EDIT-401 for hyperlipidemia. The company's stock performance shows a year-to-date return of 14.63% but significant declines over longer periods.

Editas Medicine stock has November 9, 2026 earnings date

https://www.ad-hoc-news.de/boerse/news/nebenwerte/editas-medicine-stock-has-november-9-2026-earnings-date/70331568
Editas Medicine (EDIT) is scheduled to report its next earnings on November 9, 2026. The company's second-quarter revenue reached USD 11.89 million, significantly up from USD 2.83 million in the first quarter, while its stock was trading at EUR 2.14 at Lang & Schwarz and USD 2.40 on Nasdaq on October 15, 2026. Editas Medicine, a biotech company developing CRISPR-based genomic medicines, had a market capitalization of USD 367.8 million and a P/E ratio of minus 3.20.

A delivery method generated engineered immune cells inside the body and depleted B cells.

https://www.stocktitan.net/news/EDIT/editas-medicine-announces-poster-presentations-at-the-european-winpndm01p7i.html
Editas Medicine (EDIT) is set to present two posters at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress in Hamburg, Germany, on October 28, 2026. The presentations will cover novel targeted lipid nanoparticle delivery for in vivo CAR-T cell generation and a GMP-ready manufacturing platform for these therapeutics. Additionally, management will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference in Boston on November 10, 2026.

Editas Medicine to present gene editing research at ESGCT congress By Investing.com

https://ng.investing.com/news/stock-market-news/editas-medicine-to-present-gene-editing-research-at-esgct-congress-93CH-2736325
Editas Medicine (NASDAQ:EDIT) announced it will present two posters at the European Society of Gene and Cell Therapy 33rd Annual Congress in Hamburg, Germany, from October 27-30, 2026. The presentations will cover research on targeted lipid nanoparticle delivery for in vivo CAR-T cell generation and B-cell depletion, as well as the development of a manufacturing platform for targeted LNP therapeutics. Additionally, Editas Medicine management will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026.
Advertisement

Editas Medicine to present gene editing research at ESGCT congress

https://www.investing.com/news/company-news/editas-medicine-to-present-gene-editing-research-at-esgct-congress-93CH-4949357
Editas Medicine announced it will present two posters at the European Society of Gene and Cell Therapy 33rd Annual Congress in October 2026, focusing on targeted lipid nanoparticle delivery for in vivo CAR-T cell generation and B-cell depletion, and a manufacturing platform for LNP therapeutics. The company will also participate in the Guggenheim 3rd Annual Healthcare Innovation Conference in November 2026. These presentations will highlight their CRISPR genome editing research and technology.

Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference

https://www.globenewswire.com/news-release/2026/10/14/3380791/0/en/editas-medicine-announces-poster-presentations-at-the-european-society-of-gene-and-cell-therapy-esgct-33rd-annual-congress-and-participation-in-upcoming-investor-conference.html
Editas Medicine announced it will present two posters at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress from October 27-30, 2026, in Hamburg, Germany, detailing novel LNP delivery for CAR-T cell generation and a GMP-ready manufacturing platform. Additionally, the company's management will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026. These events highlight Editas Medicine's ongoing advancements in gene editing and engagement with scientific and investment communities.

Editas Medicine to present gene editing research at ESGCT congress By Investing.com

https://in.investing.com/news/stock-market-news/editas-medicine-to-present-gene-editing-research-at-esgct-congress-93CH-5633122
Editas Medicine (NASDAQ:EDIT) announced it will present two posters at the European Society of Gene and Cell Therapy 33rd Annual Congress in October 2026. The presentations will detail research on targeted lipid nanoparticle delivery for in vivo CAR-T cell generation and B-cell depletion, and the development of a manufacturing platform for targeted LNP therapeutics. Additionally, Editas Medicine management will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference in November 2026.

Editas Medicine Q3 2026 Earnings Date and Estimates

https://www.marketbeat.com/earnings/reports/2026-11-9-editas-medicine-inc-stock/
Editas Medicine (NASDAQ:EDIT) is projected to report its Q3 2026 earnings on Monday, November 9, 2026, before market open, with a conference call scheduled for November 3, 2026, at 4:00 PM ET. Analysts anticipate an EPS of -$0.21 on revenues of $4.54 million, a decrease from the prior year's revenue of $7.54 million. The company's recent track record shows it has beaten consensus EPS estimates in 5 out of its last 8 quarters.

Editas: Downgrade To 'Hold' On Reni-Cel Discontinuation SCD/TDT And EDIT-401 Strategic Shift

https://seekingalpha.com/article/4953511-editas-downgrade-hold-reni-cel-discontinuation-scdtdt-and-edit-401-strategic-shift
Editas Medicine has been downgraded from "Buy" to "Hold" due to a strategic pivot and execution setbacks, including the discontinuation of reni-cel after failing to secure a partner. The company is now focusing on its in vivo CRISPR-Cas9 therapy, EDIT-401, for HeFH, with initial safety data expected in Q1 2027. Despite cost reductions extending the cash runway into 2H 2028, clinical proof-of-concept for the new focus remains unproven.
Advertisement

Editas Medicine Gets Clearance For First Human Trial Of Gene-Editing Drug – Wells Fargo Sees Potential For Major Value Upside In 2027

https://finance.yahoo.com/news/editas-medicine-gets-clearance-first-172510786.html
Editas Medicine received clearance for its gene-editing treatment, EDIT-401, to begin human clinical trials in Australia. Wells Fargo subsequently upgraded Editas stock to 'Overweight' with a $6 price target, anticipating significant value upside in 2027 if early trial results for the cholesterol-reducing drug are positive. EDIT-401 aims to provide a single-treatment solution for high cholesterol, a major differentiator from existing medications.

Editas Medicine, Inc. (EDIT) stock price, news, quote and history

https://au.finance.yahoo.com/quote/EDIT/
This article provides a comprehensive overview of Editas Medicine, Inc. (EDIT) stock, including its current price, historical performance, and key financial metrics. It details the company's focus on developing genomic medicines using CRISPR technology, highlighting its lead program EDIT-401 for hyperlipidemia and other therapies for sickle cell disease. The report also includes analyst ratings, earnings trends, and a performance comparison against the S&P 500.

Wells Fargo Upgrades Editas Medicine to Overweight From Equal Weight, $6 Price Target

https://www.marketscreener.com/news/wells-fargo-upgrades-editas-medicine-to-overweight-from-equal-weight-6-price-target-ce785ddfda89f121
Wells Fargo has upgraded Editas Medicine (EDIT) to Overweight from Equal Weight, setting a new price target of $6. This upgrade comes as Editas Medicine also received approval in Australia for a Phase 1/2 trial of EDIT-401, a gene-editing therapy. The news contributed to a rise in Editas Medicine's shares.

An experimental gene-editing drug kept monkeys' bad cholesterol about 90% lower for 10 months

https://www.stocktitan.net/news/EDIT/editas-medicine-receives-approval-to-initiate-first-in-human-3en32jw2635o.html
Editas Medicine has received approval in Australia to begin its first-in-human Phase 1/2 Strive clinical trial for EDIT-401, targeting inherited high cholesterol. Preclinical studies in non-human primates showed an approximately 90% reduction in LDL-C maintained over 10 months. The company expects to start patient dosing in 2026, with initial safety and tolerability data anticipated in Q1 2027 and topline results later that year.

Editas Medicine receives approval to start EDIT-401 trial in Australia

https://www.investing.com/news/company-news/editas-medicine-receives-approval-to-start-edit401-trial-in-australia-93CH-4938522
Editas Medicine has received approval to commence its Phase 1/2 Strive clinical trial for EDIT-401 in Australia, targeting patients with Heterozygous Familial Hypercholesterolemia. The company has also applied for approval in New Zealand, with preclinical data showing significant LDL-C reduction maintained over 10 months. The trial will evaluate the safety, tolerability, and efficacy of a single dose of EDIT-401, with initial safety data expected in Q1 2027 and topline results for Part 1 later in the same year.
Advertisement

Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia

https://www.globenewswire.com/news-release/2026/10/08/3377124/0/en/editas-medicine-receives-approval-to-initiate-first-in-human-clinical-trial-of-edit-401-in-patients-with-hyperlipidemia.html
Editas Medicine has received approval to initiate its Phase 1/2 Strive™ clinical trial of EDIT-401 for patients with Heterozygous Familial Hypercholesterolemia (HeFH) in Australia, with submission also made for New Zealand. The company plans to begin patient dosing this year and report initial safety and tolerability data in Q1 2027. Additionally, new preclinical data demonstrating the durability of EDIT-401's LDL-C reduction will be presented at the American Heart Association Scientific Sessions 2026.

Editas Medicine Gets Clearance For First Human Trial Of Gene-Editing Drug – Wells Fargo Sees Potential For Major Value Upside In 2027

https://stocktwits.com/news-articles/markets/equity/editas-medicine-gets-clearance-for-first-human-trial-of-gene-editing-drug/cZDUoyRRBND
Editas Medicine received approval to begin its first human clinical trial for EDIT-401, a gene-editing treatment for high cholesterol. Wells Fargo upgraded Editas stock to 'Overweight' with a $6 price target, anticipating significant valuation upside in 2027 if early trial results show promising cholesterol reductions. The drug, which showed a 90% reduction in bad cholesterol in animal studies, is expected to begin patient dosing this year with initial safety data due in Q1 2027.

Update: Editas Medicine Shares Rise After Australia Clears Phase 1/2 Trial of EDIT-401

https://finance.yahoo.com/healthcare/articles/editas-medicine-shares-rise-australia-182552099.html
Editas Medicine shares rose after Australia approved a Phase 1/2 trial for its experimental treatment EDIT-401. The article, from MT Newswires, also notes a Wells Fargo upgrade, but the full details are behind a premium subscription.

Editas Medicine stock gained 2.75 percent on October 7, 2026

https://www.ad-hoc-news.de/boerse/news/nebenwerte/editas-medicine-stock-gained-2-75-percent-on-october-7-2026/70260576
Editas Medicine (EDIT) saw its stock rise by 2.75 percent on October 7, 2026, trading at USD 2.81. The company reported a significant increase in Q2 2026 revenue to USD 11.89 million, up from USD 3.58 million year-over-year, and has a cash runway extending into the second half of 2028. Analysts maintain a "Moderate Buy" consensus with an average target price of USD 5.80.

Guggenheim upgrades Editas Medicine stock to Buy

https://www.ad-hoc-news.de/boerse/news/nebenwerte/guggenheim-upgrades-editas-medicine-stock-to-buy/70247328
Guggenheim upgraded Editas Medicine (EDIT) stock from Neutral to Buy, setting a USD 5.00 price target. This upgrade follows Editas's second-quarter 2026 revenue increase to USD 11.89 million and a reduced net loss, driven by deferred revenue recognition from a Bristol Myers collaboration. The company's cash reserves of USD 211.6 million are projected to fund operations into the second half of 2028, supporting the development of EDIT-401 for familial hypercholesterolemia.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement